ELORA-TRZ 20 mg, SRP Custom Research Compound
ELORA-TRZ pairs 10 mg of eloralintide (Elora) with 10 mg of tirzepatide (TRZ) in one lyophilized vial. The 20 mg listing describes total peptide content per vial, not a concentration or a recommended dose. It is supplied for controlled laboratory investigations of amylin-associated signaling alongside incretin receptor biology.
Formula breakdown
| Eloralintide (Elora) | 10 mg |
|---|---|
| Tirzepatide (TRZ) | 10 mg |
| Total peptide content | 20 mg |
| Format | Lyophilized research powder |
| Formula type | SRP custom research blend, 1:1 listed mass ratio |
How the ingredients work in research models
Eloralintide: a selective amylin receptor agonist studied in receptor-signaling and metabolic-response investigations. Amylin biology provides context for laboratory studies of satiety-associated signaling, gastric-emptying models and nutrient-response regulation.
Tirzepatide: a dual GIP and GLP-1 receptor agonist. Its research focus includes receptor activation, cellular signaling and glucose-response biology.
What the combination allows researchers to ask
The two-component format provides a material for evaluating interactions between these pathways in an appropriately controlled model. Relevant questions include whether responses differ from each ingredient alone and whether the components retain their expected analytical and signaling profiles when combined. Ingredient studies do not establish synergy, safety, stability or effectiveness of the finished SRP blend.
Cold-container shipping
ELORA-TRZ ships in a cold container. The total U.S. shipping charge is $25 once per order containing ELORA-TRZ, whether the order contains one vial, multiple vials or additional products. It is not a $25 per-vial charge. Follow the handling information supplied with your shipment; transit packaging is not a shelf-life specification.
Research references
- Eloralintide, a selective, long-acting amylin receptor agonist: phase 1 proof of concept. Background on the individual ingredient and amylin biology.
- LY3298176 (tirzepatide), a dual GIP and GLP-1 receptor agonist: discovery to clinical proof of concept. Receptor-characterization and translational research on tirzepatide.
These publications concern study-manufactured materials and do not represent testing of this SRP vial.
Explore the formula
Read the ELORA-TRZ research guide · Compare standalone Eloralintide 20 mg · Explore SRP Custom Compounds · Ask SRP a product question
Research use only. Supplied exclusively for laboratory research and development. Not intended for human or animal consumption, administration, medical, diagnostic or therapeutic use.
Reviews
There are no reviews yet.